Drugs / AZD7325
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 112 trials | ||||||
| Phase 1 | NCT03140813 | Jan 2018 → Jun 2020 | fragile X syndrome | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 1 | NCT02530580 | Feb → Jul 2016 | — | University College, London | Completed | No outcome recorded |
| Phase 1 | NCT02135198 | Sep 2014 → Aug 2015 | — | University College, London | Completed | No outcome recorded |
| Phase 1 | NCT00940641 | Aug → Oct 2009 | — | AstraZeneca | Suspended | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00945425 | Jul → Nov 2009 | — | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT00902772 | May → Sep 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00901290 | May → Sep 2009 | — | AstraZeneca | Suspended | No outcome recorded |
| Phase 1 | NCT00769899 | Oct 2008 → Mar 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00790114 | Jul → Sep 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00720421 | Jun → Aug 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00681915 | Mar → Jul 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00681720 | Feb → Jul 2008 | anxiety | AstraZeneca | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00807937 | Dec 2008 → May 2009 | generalized anxiety disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00808249 | Dec 2008 → May 2009 | anxiety disorder | AstraZeneca | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03678129 | Dec 2018 → Jun 2025 | autism spectrum disorder | King's College London | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01966679 Comparator | Oct 2013 → Jul 2015 | autism spectrum disorder | University of California, Los Angeles | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-11-06 | Axsome Therapeutics, Inc. | Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy gcs-web.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD7325 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00940641 ↗ |
| Action | Activate | “AZD7325 and AZD6280 are novel, subtype-selective GABAAα2,3 receptor positive modulators with limited sedative effects.” PMID 28013354 ↗ Dec 20162“GABA receptor alpha-2 subunit positive allosteric modulator” CHEMBL1783282 ↗ “GABA receptor alpha-3 subunit positive allosteric modulator” CHEMBL1783282 ↗ |
| Modality | Small molecule | — CHEMBL1783282 ↗ |
| Route | Oral | “Single dose of oral solution or capsule.” NCT00681720 ↗ |
| Target | GABRA2 | “GABA receptor alpha-2 subunit positive allosteric modulator” CHEMBL1783282 ↗ |
| Target | GABRA3 | “GABA receptor alpha-3 subunit positive allosteric modulator” CHEMBL1783282 ↗ |